611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Health Sciences
Resources
Basic InformationLatest News
Extinct Human Species Passed on Powerful Immune System GeneScientists ID Genes Tied to Left-HandednessScientists Creating Gene Map of Human 'Microbiome'New DNA Blood Test May Help Guide Breast Cancer TreatmentFootball Head Trauma Linked Again to Long-Term Brain DamageMore 'Buyer Beware' Warnings for Unregulated Stem Cell Clinics3-D Printers Might Someday Make Replacement HeartsOne Gene Change 2 Million Years Ago Left Humans Vulnerable to Heart AttackHow to Protect Your DNA for Big Health BenefitsBones Help Black People Keep Facial Aging at BayGene Test Might Someday Gauge Your Heart Attack RiskYour Gut Bacteria Could Affect Your Response to MedsIt's Never Too Late for New Brain CellsSensor-Laden Glove Helps Robotic Hands 'Feel' ObjectsAn Antibiotic Alternative? Using a Virus to Fight BacteriaBrain Sharpens the Hearing of the Blind, Study FindsMind-Reading Tech Could Bring 'Synthetic Speech' to Brain-Damaged PatientsCan Obesity Shrink Your Brain?Will You Get Fat? Genetic Test May TellMagnet 'Zap' to the Brain Might Jumpstart Aging MemoryWhy More Patients Are Surviving an AneurysmIsraeli Team Announces First 3D-Printed Heart Using Human CellsPoverty Could Leave Its Mark on GenesNFL Retirees Help Scientists Develop Early Test for Brain Condition CTEBrain 'Zap' Might Rejuvenate Aging MemoryLab-Grown Blood Vessels Could Be Big Medical AdvanceOnly Spoken Words Processed in Newly Discovered Brain RegionSmall Trial Provides New Hope Against Parkinson's DiseaseInsomnia May Be in Your Genes'Miracle' Young Blood Infusion Treatments Unproven, Potentially Harmful: FDAPossible Parkinson's 'Pandemic' Looms: ReportScience Puzzling Out Differences in Gut Bacteria Around the World'Mind-Reading' AI Turns Thoughts Into Spoken WordsEat What You Want and Still Stay Slim? Thank Your GenesGood News, Bad News on Levodopa for Parkinson's DiseaseNature or Nurture? Twins Study Helps Sort Out Genes' Role in DiseaseBeing Bullied May Alter the Teen BrainFDA Warns Companies on Dangerous, Unapproved Stem Cell TreatmentsGene Tweaking Prevented Obesity in MiceApproach That New Gene Testing Kit With CautionResearch on Almost 2,000 Brains Brings Insight Into Mental IllnessRestoring Hair Growth on Scarred Skin? Mouse Study Could Show the WayParkinson's Gene Therapy Wires New Brain CircuitsNext for Disabling Back Pain? New Discs From Patients' Own CellsSkin 'Glow' Test Might Someday Spot Disease Risk EarlyComputer-Brain Link Helps 'Locked In' People Chat, Surf WebCould a Natural Protein Help Fight Obesity?Blood Test May One Day Help Track Concussion RecoveryThe Bigger the Brain, the Bigger the Tumor Risk?Gene Therapy for Parkinson's Symptoms Shows Promise
Questions and AnswersLinksBook Reviews
Related Topics

Medical Disorders
Mental Disorders
Mental Health Professions

Parkinson's Gene Therapy Wires New Brain Circuits

HealthDay News
by By Amy Norton
HealthDay Reporter
Updated: Nov 28th 2018

new article illustration

WEDNESDAY, Nov. 28, 2018 (HealthDay News) -- An experimental gene therapy for Parkinson's disease seems to work by rewiring key areas of the brain, a new study finds.

The researchers focused on 15 Parkinson's patients who, in an earlier trial, had received so-called GAD gene therapy. GAD is an enzyme that spurs the production of a brain chemical involved in movement control.

In the previous trial, patients had shown improvements in their movement problems after receiving infusions of the GAD gene into the brain.

What hadn't been clear was precisely why, said researcher Dr. David Eidelberg, who directs the Center for Neurosciences at the Feinstein Institute for Medical Research, in Manhasset, N.Y.

So for the new study, Eidelberg's team examined specialized brain scans from 15 of the trial patients. The investigators found an unexpected answer: The gene therapy did not change the abnormal brain circuitry that marks Parkinson's disease.

Instead, it essentially rewired a small area of the brain, to partially compensate for the faulty circuitry.

"It created its own set of circuits," Eidelberg explained. "The disease circuitry continues -- so this is not a cure."

Still, he said, the gene therapy seems to spur new brain connections that can benefit people with Parkinson's.

The study findings were published online Nov. 28 in Science Translational Medicine.

Parkinson's disease affects nearly 1 million people in the United States alone, according to the Parkinson's Foundation.

The root cause is unclear, but as the disease progresses, the brain loses cells that produce dopamine -- a chemical that regulates movement. As a result, people suffer symptoms like tremors, stiff limbs, and balance and coordination problems that gradually worsen over time.

There are treatments to lessen those symptoms, including medications that boost dopamine levels or mimic the actions of dopamine. Another option for some patients is deep brain stimulation (DBS), where electrodes are implanted in a specific brain area to deliver continuous electrical pulses. It's thought to help by suppressing abnormal electrical activity.

GAD gene therapy is done by inserting the gene into an inactivated cold virus. That viral "vector" is infused into a specific brain area called the subthalamic nucleus -- which is one of the brain regions targeted in DBS treatment.

Originally, Eidelberg added, researchers thought the gene therapy would work in a "DBS-like" way.

But based on the new findings, that's not the case.

Dr. Michael Okun is medical director of the Parkinson's Foundation. He called the study "fascinating."

"It showed that GAD gene therapy, unlike subthalamic nucleus DBS, did not change the expected Parkinson's disease brain network," Okun said. "Instead, it co-opted adjacent non-motor pathways."

Why does that matter? One reason, according to Okun, is that it offers an "important lesson" for the gene therapy field going forward.

Researchers cannot make assumptions about a therapy's "mechanism of action," he said, based on the brain area it targets.

Eidelberg made another point: In future studies, researchers could use brain imaging to be sure that patients' symptom improvements are due to a true effect of the gene therapy -- rather than a "placebo effect."

In the original trial, which involved a few dozen Parkinson's patients, some were randomly assigned to receive GAD gene infusions. The rest underwent a "sham" procedure for comparison.

Over six months, both groups showed improvements in movement symptoms like stiffness and tremor. But the gene therapy group saw greater gains.

"It wasn't a slam dunk," Eidelberg stressed. "But they were doing better. And that persisted to the one-year mark."

With any such therapy, there is a theoretical concern that the infused gene will have unintended effects.

"What we've seen is that this gene stays put," Eidelberg said. "It doesn't percolate all over the brain."

In the original trial, there were no red flags, according to the researchers. The most common side effects were temporary headaches and nausea.

Various research teams are looking at different approaches to gene therapy for Parkinson's. The hope, Eidelberg said, is to develop additional options that work for at least some patients -- possibly freeing them from taking daily medications.

At this point, he noted, there is "a lot of interest" in doing a larger, later-stage trial of the GAD therapy. But none has begun yet.

The current study was funded by Neurologix Inc., the company that developed the gene therapy.

More information

The Parkinson's Foundation has more on Parkinson's treatment.